GLTO logo

Galecto, Inc. Stock Price

NasdaqCM:GLTO Community·US$47.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

GLTO Share Price Performance

US$29.61
25.01 (543.70%)
US$29.61
25.01 (543.70%)
Price US$29.61

GLTO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with medium-low risk.

6 Risks
1 Reward

Galecto, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$15.8m

Other Expenses

-US$15.8m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-9.93
0%
0%
0%
View Full Analysis

About GLTO

Founded
2011
Employees
5
CEO
Hans Schambye
WebsiteView website
galecto.com

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Recent GLTO News & Updates

Recent updates

No updates